logo

Provention Bio, Inc. (PRVB)



Trade PRVB now with
  Date
  Headline
1/5/2023 4:02:30 PM Provention Bio Appoints Rita Jain To Board Of Directors
11/3/2022 7:23:09 AM Provention Bio Q3 Net Loss $28.6 Mln Vs. Net Loss $27.0 Mln Last Year
10/6/2022 7:14:15 AM Provention Bio Enters Co-promotion Agreement With Sanofi U.S. For Launch Of Provention's Teplizumab
8/4/2022 7:56:43 AM Provention Bio Q2 Net Loss $29.7 Mln, Or $0.46/shr Vs Net Loss Of $29.1 Mln Or $0.46/shr Prior Year
6/3/2022 7:36:32 AM Provention Bio Grants Stock Options To Eight New Employees To Purchase 166,000 Shares
3/28/2022 7:39:26 AM Provention Bio Reports Positive Final Results From First-In-Human Study Of Coxsackievirus B Vaccine Candidate PRV-101
2/24/2022 7:20:36 AM Provention Bio Q4 Net Loss $25.8 Mln Or $0.41/shr Vs Net Loss Of $32.6 Mln Or $0.58/shr Prior Year
2/22/2022 7:32:32 AM Provention Bio Resubmits BLA For Teplizumab For Delay Of Clinical Type 1 Diabetes In At-risk Individuals
1/7/2022 7:32:33 AM Provention Bio Announces The Grant Of Inducement Awards
12/2/2021 7:33:21 AM Provention Bio Announces Grant Of Inducement Awards To Purchase An Aggregate Of 550K Shares